Optimizing drug dosing for the treatment of chronic lymphocytic Leukemia

Nitin Jain

Optimizing drug dosing for the treatment of chronic lymphocytic Leukemia

Leukemia

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	330-331
Number of pages	2
Journal	Clinical Advances in Hematology and Oncology
Volume	17
Issue number	6
State	Published - Jun 2019

ASJC Scopus subject areas

Hematology
Oncology

Cite this

@article{daab92d246c944beaa4bf236255db9ea,

title = "Optimizing drug dosing for the treatment of chronic lymphocytic Leukemia",

author = "Nitin Jain",

note = "Funding Information: Dr Jain has received research funding from Pharmacyclics, AbbVie, Genentech, BMS, and AstraZeneca. He has received honoraria from Pharmacyclics, Janssen, AbbVie, Genentech, and AstraZeneca.",

year = "2019",

month = jun,

language = "English (US)",

volume = "17",

pages = "330--331",

journal = "Clinical Advances in Hematology and Oncology",

issn = "1543-0790",

publisher = "Millennium Medical Publishing, Inc.",

number = "6",

}

TY - JOUR

T1 - Optimizing drug dosing for the treatment of chronic lymphocytic Leukemia

AU - Jain, Nitin

N1 - Funding Information: Dr Jain has received research funding from Pharmacyclics, AbbVie, Genentech, BMS, and AstraZeneca. He has received honoraria from Pharmacyclics, Janssen, AbbVie, Genentech, and AstraZeneca.

PY - 2019/6

Y1 - 2019/6

UR - http://www.scopus.com/inward/record.url?scp=85068781791&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068781791&partnerID=8YFLogxK

M3 - Comment/debate

C2 - 31437134

AN - SCOPUS:85068781791

SN - 1543-0790

VL - 17

SP - 330

EP - 331

JO - Clinical Advances in Hematology and Oncology

JF - Clinical Advances in Hematology and Oncology

IS - 6

ER -

Optimizing drug dosing for the treatment of chronic lymphocytic Leukemia

ASJC Scopus subject areas

Other files and links

Cite this